Tevogen Bio Holdings Inc. (TVGN) Balance Sheet
TVGN balance sheet, FY2026
June 30, 2026 · U.S. dollars$4.4M assets = $12.6M liabilities + −$8.2M equity
Liabilities exceed assets: shareholders’ equity is negative (−$8.2M).
Both columns are drawn to the same scale: what TVGN owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TVGN financial health
Descriptive bands, not a rating. Fiscal FY2026.
TVGN balance sheet trends, FY2022–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $7.7MFY2022 | $4.4MFY2026 | −13.0%/yr | |
| Total liabilities | $24.1MFY2022 | $12.6MFY2026 | −15.0%/yr | |
| Shareholders’ equity | −$16.5MFY2022 | −$8.2MFY2026 | — | |
| Cash & short-term investments | $7.1MFY2022 | $552,372FY2026 | −47.2%/yr | |
| Total debt | $23.5MFY2022 | $3.1MFY2026 | −39.7%/yr | |
| Net cash (debt) | −$16.4MFY2022 | −$2.5MFY2026 | +$13.8M | |
| Working capital | $6.5MFY2022 | −$5.5MFY2026 | −$12.0M | |
| Book value per share | −$14.15FY2023 | −$2.48FY2026 | — | |
| Current ratio | 10.74FY2022 | 0.22FY2026 | −10.52 | |
| Shares outstanding | 2.4MFY2023 | 3.3MFY2026 | +11.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TVGN assets
TVGN liabilities and equity
TVGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TVGN balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $552,372 | $1.3M | $1.1M | $5.5M | $7.1M |
| Cash & equivalents | $552,372 | $1.3M | $1.1M | $5.5M | $7.1M |
| Receivables | $158,819 | $158,819 | $344,500 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $828,592 | $919,088 | $326,082 | $352,977 | $53,963 |
| Total current assets | $1.5M | $2.4M | $1.7M | $5.8M | $7.2M |
| Property, plant & equipment (net) | $1.6M | $524,932 | $928,513 | $1.3M | $142,623 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.2M | $575,841 | $2.9M | $594,883 | $342,648 |
| Total assets | $4.4M | $3.5M | $5.5M | $7.7M | $7.7M |
| Liabilities | |||||
| Accounts payable | $3.3M | $5.2M | $3.4M | $865,910 | $377,997 |
| Short-term debt | $2.0M | $1.9M | $81.0M | $278,207 | — |
| Deferred revenue | — | — | — | −$375,807 | — |
| Total current liabilities | $7.1M | $9.0M | $85.5M | $2.0M | $667,944 |
| Long-term debt | $4.4M | $1.0M | $14.2M | $39.3M | $23.5M |
| Lease obligations | $1.5M | $234,859 | $487,572 | $710,933 | $0 |
| Other long-term liabilities | $1.1M | $92,976 | $234,858 | $432,726 | $0 |
| Total liabilities | $12.6M | $10.1M | $99.9M | $41.7M | $24.1M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $402 | $17,800 | $12,000 | $61,880 | $63,880 |
| Retained earnings (deficit) | −$139.7M | −$113.4M | −$99.7M | −$39.2M | −$17.1M |
| Accumulated other comprehensive income | — | — | $0 | $0 | — |
| Total shareholders' equity | −$8.2M | −$6.7M | −$94.4M | −$34.0M | −$16.5M |
| Key figures | |||||
| Total debt | $3.1M | $2.9M | $95.4M | $40.0M | $23.5M |
| Net cash (debt) | −$2.5M | −$1.6M | −$94.4M | −$34.5M | −$16.4M |
| Working capital | −$5.5M | −$6.7M | −$83.8M | $3.9M | $6.5M |
| Tangible book value | −$8.2M | −$6.7M | −$94.4M | −$34.0M | −$16.5M |
| Book value per share | −$2.48 | −$2.28 | −$28.54 | −$14.15 | — |
| Shares outstanding | 3.3M | 2.9M | 3.3M | 2.4M | — |
| Current ratio | 0.22 | 0.26 | 0.02 | 2.98 | 10.74 |
| Quick ratio | 0.10 | 0.16 | 0.02 | 2.80 | 10.66 |
| Equity / assets | −187.9% | −192.8% | −1,715.2% | −438.7% | −215.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.1M | $692,305 | $552,372 | $1.0M | $685,229 | $2.0M | $1.3M | $2.3M | $1.1M | $1.3M | $1.1M | $2.6M |
| Cash & equivalents | $1.1M | $692,305 | $552,372 | $1.0M | $685,229 | $2.0M | $1.3M | $2.3M | $1.1M | $1.3M | $1.1M | $2.6M |
| Receivables | $0 | $0 | $158,819 | $158,819 | $158,819 | $158,819 | $0 | $158,819 | $158,819 | $158,819 | $344,500 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $927,105 | $1.4M | $828,592 | $925,821 | $1.2M | $944,056 | $1.1M | $1.0M | $1.2M | $923,202 | $326,082 | $156,796 |
| Total current assets | $2.0M | $2.1M | $1.5M | $2.1M | $2.1M | $3.1M | $2.4M | $3.5M | $2.4M | $2.4M | $1.7M | $2.8M |
| Property, plant & equipment (net) | $1.5M | $1.5M | $1.6M | $1.6M | $1.6M | $419,530 | $524,932 | $628,479 | $730,220 | $830,210 | $928,513 | $1.0M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.2M | $1.2M | $1.2M | $756,807 | $565,884 | $575,841 | $575,841 | $133,276 | $133,276 | $133,276 | $2.9M | $2.6M |
| Total assets | $4.7M | $4.9M | $4.4M | $4.5M | $4.3M | $4.1M | $3.5M | $4.3M | $3.3M | $3.4M | $5.5M | $6.4M |
| Liabilities | ||||||||||||
| Accounts payable | $2.8M | $3.8M | $3.3M | $3.3M | $4.2M | $4.7M | $5.2M | $5.8M | $6.7M | $5.2M | $3.4M | $1.9M |
| Short-term debt | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $1.8M | — | $2.9M | $1.9M | $1.9M | $81.0M | $64.0M |
| Deferred revenue | — | — | — | — | — | — | — | −$250,000 | −$6.7M | $1.6M | — | −$1.9M |
| Total current liabilities | $6.2M | $7.3M | $7.1M | $6.7M | $8.1M | $8.7M | $9.0M | $10.4M | $10.6M | $8.9M | $85.5M | $67.7M |
| Long-term debt | $6.4M | $6.4M | $4.4M | $4.4M | $4.4M | $3.0M | $1.0M | $0 | $0 | $0 | $14.2M | $0 |
| Lease obligations | $1.4M | $1.4M | $1.5M | $1.5M | $1.5M | $170,851 | $234,859 | $301,074 | $365,481 | $427,371 | $487,572 | — |
| Other long-term liabilities | $1.1M | $1.1M | $1.1M | $1.2M | $1.3M | $73,323 | $92,976 | $64,203 | $332,208 | $227,761 | $234,858 | $29.5M |
| Total liabilities | $13.6M | $14.8M | $12.6M | $12.3M | $13.8M | $11.8M | $10.1M | $10.5M | $10.9M | $9.2M | $99.9M | $97.2M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $426 | $417 | $402 | $19,740 | $19,370 | $18,390 | — | $17,078 | $16,883 | $16,462 | $12,000 | $61,880 |
| Retained earnings (deficit) | −$150.9M | −$145.1M | −$139.7M | −$135.0M | −$129.3M | −$123.8M | −$113.4M | −$103.9M | −$98.1M | −$88.4M | −$99.7M | −$96.0M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | −$2.8M | $0 | $0 | $0 |
| Total shareholders' equity | −$8.9M | −$9.8M | −$8.2M | −$7.8M | −$9.5M | −$7.7M | −$6.7M | −$6.2M | −$7.6M | −$5.8M | −$94.4M | −$90.8M |
| Key figures | ||||||||||||
| Total debt | $3.0M | $3.1M | $3.1M | $7.5M | $7.6M | $4.8M | $1.0M | $3.0M | $2.0M | $2.1M | $95.4M | $93.5M |
| Net cash (debt) | −$2.0M | −$2.4M | −$2.5M | −$6.5M | −$6.9M | −$2.8M | $282,995 | −$633,859 | −$881,091 | −$760,471 | −$94.4M | −$90.9M |
| Working capital | −$4.1M | −$5.1M | −$5.5M | −$4.6M | −$6.0M | −$5.6M | −$6.7M | −$6.9M | −$8.2M | −$6.5M | −$83.8M | −$64.9M |
| Tangible book value | −$8.9M | −$9.8M | −$8.2M | −$7.8M | −$9.5M | −$7.7M | −$6.7M | −$6.2M | −$7.6M | −$5.8M | −$94.4M | −$90.8M |
| Book value per share | −$2.32 | −$2.82 | −$2.48 | −$2.00 | −$2.57 | −$2.39 | −$1.87 | −$1.82 | −$2.48 | −$2.04 | −$29.19 | −$28.71 |
| Shares outstanding | 3.8M | 3.5M | 3.3M | 3.9M | 3.7M | 3.2M | 3.6M | 3.4M | 3.1M | 2.8M | 3.2M | 3.2M |
| Current ratio | 0.33 | 0.29 | 0.22 | 0.31 | 0.25 | 0.35 | 0.26 | 0.34 | 0.23 | 0.27 | 0.02 | 0.04 |
| Quick ratio | 0.18 | 0.10 | 0.10 | 0.18 | 0.10 | 0.24 | 0.14 | 0.24 | 0.12 | 0.17 | 0.02 | 0.04 |
| Equity / assets | −188.0% | −200.0% | −187.9% | −174.1% | −222.2% | −189.5% | −192.8% | −144.3% | −230.6% | −172.5% | −1,715.2% | −1,426.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
TVGN financial position
At the end of fiscal 2026 (June 30, 2026), Tevogen Bio had total assets of $4.4 million (up 26.6% from a year earlier), total liabilities of $12.6 million and shareholders' equity of -$8.2 million. It held $0.6 million in cash and short-term investments against $3.1 million of debt, net debt of $2.5 million. Its current ratio was 0.22.
Related: TVGN income statement, TVGN cash flow statement, TVGN key metrics. See the TVGN stock overview for the latest quote and news.
TVGN balance sheet FAQ
What are Tevogen Bio's total assets?
Tevogen Bio reported total assets of $4.4 million at the end of fiscal 2026 (June 30, 2026), compared with $3.5 million a year earlier.
How much debt does Tevogen Bio have?
Tevogen Bio had $3.1 million of total debt at the end of fiscal 2026, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Tevogen Bio have?
Tevogen Bio held $0.6 million in cash and short-term investments at the end of fiscal 2026; with $3.1 million of debt that is net debt of $2.5 million.
What is Tevogen Bio's book value?
Tevogen Bio's shareholders' equity (book value) was -$8.2 million at the end of fiscal 2026, or −$2.48 per share.
What is Tevogen Bio's current ratio?
Tevogen Bio had current assets of $1.5 million and current liabilities of $7.1 million, a current ratio of 0.22 (current liabilities exceed current assets).